Aberrant ELF4 expression is implicated in cancer cell proliferation, stemness, and therapy resistance across multiple malignancies, including leukemia (Sashida et al. 2009), ovarian cancer (Yao et al. 2007), glioma (Bazzoli et al. 2012), cervical cancer (Guo et al. 2019), hepatocellular carcinoma (Sze et al. 2021), and colorectal cancer (Chen et al. 2023). Here, ELF4 is linked to cancer.